FORMULATION ARTICLES
-
Engineering RNA Payload Distribution In LNPs To Unlock Higher In Vivo Gene Editing Efficiency
New research shows RNA payload distribution inside LNPs — not just encapsulation efficiency — may be key to unlocking stronger in vivo gene editing performance.
-
Beyond Guanidine: Scientists Discover A Mysterious Riboswitch Variant With A Different Biological Target
Scientists identified a mysterious riboswitch variant that resembles guanidine sensors but likely evolved to detect an entirely different metabolite.
-
RNA Modification-Mediated Translational Control In Immune Cells
Exploring how m6A RNA modifications control immune cell translation, influencing inflammation, tumor immunity, T cell activation, and future immunotherapies.
-
Validation Of A RIG-I–Based Functional Assay For Quantitative Detection Of Double-Stranded RNA Impurities In mRNA Drug Substance
A validated RIG-I assay adds a biology-informed layer to dsRNA testing by quantifying immunogenic impurities in IVT-derived mRNA therapeutics for deeper functional insight.
-
Suppressor tRNA Therapeutics: A New Frontier In Treating Genetic Disease
Suppressor tRNAs could unlock a scalable new way to treat genetic diseases caused by nonsense mutations, restoring full-length proteins across multiple indications.
-
Engineering Transient In Vivo CAR-T: Extending Expression, Expanding Access, And Rethinking Immune Reset
In this Q&A, Michael Lam, Ph.D., explores how circular RNA and targeted delivery extend transient CAR expression to enable deep B-cell depletion and controllable immune reset.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Manufacturing RNA-containing LNPs demands specialized expertise. Explore some of the challenges of RNA-LNP drug manufacturing and the advantages of outsourcing RNA-LNP formulations.
-
By following some of the best practices in freezing mRNA, you can effectively balance product quality, cost-effectiveness, process safety, and efficiency.
-
Cell therapy’s future depends on smarter gene delivery. Learn how lipid nanoparticles offer a scalable, cell-friendly alternative to electroporation and viral vectors for manufacturing efficiency.
-
Discover how mRNA technologies open the doors to a whole range of new gene therapies and the role of lipid nanoparticles (LNPs) in current and future developments.
-
The path to regulatory approval for LNPs demands carefully considered strategies. By adopting proactive and strategic approaches, developers can overcome regulatory hurdles on the path to approval.
-
Both physical and chemical nonviral gene delivery systems for ex vivo genetic modification offer advantages over viral vectors, including smaller scale production and the low risk of immunogenicity.
-
Explore how lipid nanoparticles are revolutionizing cell therapy workflows to enable the precise delivery of mRNA and gene editing tools for next-generation treatments like CAR T and HSC therapies.